Articles tagged with Cancer Patients
Acute myeloid leukemia is a cancer that affects blood cells and can lead to infection, anemia, and easy bleeding. The Georgia Cancer Center has received a $2.3 million grant to study how cancer cells resist treatment and propose new options to improve patient survival.
A Phase I and Phase II clinical trial of the immunotherapy REGN5459 resulted in a 90.5 percent overall response rate among patients with relapsed multiple myeloma. The treatment is reasonably tolerated, with common side effects including cytokine release syndrome.
Researchers have reported promising results in rare gynecologic cancers from the DART immunotherapy trial, with durable responses and complete remissions observed in patients. The findings suggest a potential new treatment approach for these previously underserved patient populations.
Researchers discuss rapamycin's potential to delay cancer onset by slowing cell proliferation and tumor progression. The mTOR pathway is involved in both cancer and aging, making rapamycin a promising chemopreventive agent.
Patients with depression before or after a breast cancer diagnosis have lower survival rates compared to those without depression. Diagnosing and treating depression at the time of breast cancer diagnosis and beyond is crucial for improved patient care and survival.
A recent clinical trial found that nearly 90% of patients with unresectable desmoplastic melanoma responded to treatment with pembrolizumab. The immunotherapy drug showed impressive results in both treatable and inoperable cases, suggesting a promising treatment option for this rare form of skin cancer.
A recent study found that immunotherapy alone resulted in a 89% favorable treatment response rate for patients with desmoplastic melanoma. This suggests that combination therapies may not be necessary for these patients, reducing the risk of toxicity.
A new meta-analysis finds that Black patients are 71% more likely to experience heart damage following chemotherapy treatment. The study highlights the need for further research into underlying factors contributing to these disparities to reduce cardiovascular risk associated with chemotherapy.
Patients with inflammatory bowel disease (IBD) are at a higher risk of developing lymphoma, particularly those with Crohn's disease. The risk is driven by both the disease activity and treatment, including immunomodulating drugs.
The S2302 Pragmatica-Lung trial is designed to be inclusive and easy to conduct, with few limits on eligibility. The study aims to answer whether a combination of ramucirumab and pembrolizumab helps patients with stage 4 non-small cell lung cancer live longer than usual treatments.
The NCCN 2023 Annual Conference emphasized the importance of fostering welcoming environments for patients and staff, ensuring care meets latest standards, and rejecting a one-size-fits-all approach. Key findings included the need to address systemic bias, social determinants of health, and staffing issues in cancer care.
Researchers found a 14.4% decline in new cancer diagnoses in 2020 compared to prior years, correlating with stay-at-home orders during the COVID-19 pandemic. The study estimates that around 200,000 people may have had undiagnosed or untreated cancer cases during this time.
Researchers found that patients with two or three separate areas of breast cancer in the same breast can opt for lumpectomies followed by whole-breast radiation therapy instead of mastectomies, resulting in better patient satisfaction and cosmetic outcomes. The study also showed that preoperative MRI scans reduced local recurrence rates.
The COVID-19 pandemic had a significant impact on cancer care, with variances in new diagnoses and disrupted care reported in the National Cancer Database. The study highlights the need for future research to understand the lasting effects of the pandemic on chronic diseases such as cancer.
Researchers at Mass General Cancer Center presented recent breakthroughs in cancer treatment, including a new mutant-selective drug that targets PI3Kα inhibitors, and innovations in whole-genome sequencing and imaging-based evaluation of cancer dependencies. These findings aim to improve the effectiveness of immunotherapy and personali...
A study led by Tokyo University of Science researchers identified Dectin-1's role in promoting colorectal cancer by enhancing PGE2 production and suppressing IL-22BP expression. The study used mouse models and clinical samples to validate the findings, which have immediate clinical implications for CRC patients.
The ACC Cardio-oncology Course aims to equip clinicians with the latest strategies and best practices for managing cardiovascular health in cancer patients. The course will feature joint presentations of oncologists and cardiologists, showcasing real-life patient care and collaboration across teams.
Recent studies have highlighted the importance of tumor microenvironment in developing and controlling triple negative breast cancer progression. Researchers suggest that technological advancements like genomics and epigenomics hold promise for overcoming TNBC's current limitations.
A team of scientists created a new, fast, and precise method for analyzing cells in tissue samples from cancer patients without the need for a trained pathologist. The method uses artificial intelligence to evaluate data produced by a technique called real-time deformability cytometry.
Researchers at Mayo Clinic Arizona have developed a new intravesical chemotherapy delivery system called TAR-200, which is safe and shows initial evidence of effectiveness in treating muscle-invasive bladder cancer (MIBC) in frail patients. The treatment has been shown to limit cancer growth while minimizing toxic effects.
Researchers propose a new method of clustering colorectal cancer patients using differential presence of exons (DPE) sequencing, which can provide valuable information on CRC progression and response to therapy. This analysis may also reduce costs and time required for staging CRC patients.
Researchers found that probiotic bacteria Lactobacillus reuteri stimulates cancer-killing T cells by secreting indole-3-aldehyde, which activates a receptor in CD8 cells. A diet rich in tryptophan enhances the effect of immunotherapy on shrinking tumors and prolonging survival.
Researchers have identified a biomarker signature that can predict which patients with kidney cancer will respond well to immunotherapy. The signature is based on the number of immune cells in and around tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
A study published in Radiology found that ultrasound is an effective standalone diagnostic method for patients with focal breast complaints. The analysis showed that ultrasound alone led to accurate diagnosis in 90% of patients, with over 80% of complaints being benign findings.
A new study published in JNCCN identifies a targeted approach to improve end-of-life conversations for people with cancer. Researchers found that specially trained oncology infusion room nurses can increase the rate of advance care planning, leading to more supported decision-making.
A UNIGE team created customizable treatments by testing drugs on artificial tumors derived from patients' cancer tissue. The approach opens the way for optimized and tailored therapies against various cancers and diseases.
A study published in the journal Cancer found that long-term pancreatic cancer survivors have a robust immune response and enriched gut microbiome species, including Faecalibacterium prausnitzii. The research suggests that these bacterial species may promote immune response to pancreas cancer.
Researchers have shown lorlatinib to be safe and effective in treating high-risk neuroblastoma with ALK gene mutations. The targeted therapy has led to a major amendment in a phase 3 clinical trial, offering new hope for patients with this often lethal cancer.
The NRG Oncology combined trial results indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma. pCR can be used as a prognostic factor for clinical outcomes in future STS research, with patients achieving higher overall and disease-free survival rates.
A phase 2 study found a 92% disease control rate with the combination of belzutifan and cabozantinib in pre-treated advanced kidney cancer patients. The treatment has a manageable safety profile, providing a potential alternative for patients experiencing disease progression on immunotherapy.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
A new study reveals that patients with blood cancers experience significant improvement in their reported well-being after receiving CAR T-cell therapy. The therapy not only improves physical symptoms but also anxiety and depression symptoms.
Researchers found that neutrophils can be pro- or anti-tumour depending on their surface markers, and those fighting tumours share cytotoxic power with neutrophils in bacterial infections. Blocking these anti-tumour neutrophils eliminates treatment benefits.
A clinical trial has established surgery as an effective treatment option for patients with early metastatic seminoma, a slow-growing form of testicular cancer. Surgery has been shown to offer better outcomes than traditional therapies like chemotherapy and radiation, with fewer long-term side effects.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.
A rapid genetic testing model identified pathogenic variants in 51 patients with advanced prostate cancer, leading to discussions of possible treatment changes for 22 patients. The streamlined approach detected actionable gene variants eligible for newer targeted therapies in nearly half of patients with these variants.
Researchers at Georgia Institute of Technology developed a synthetic tumor model to understand the impact of microenvironment on targeted therapies for Activated B Cell-like Diffuse Large B cell lymphoma. The model showed promise in demonstrating how combining therapeutics can overcome tumor resistance to inhibitors.
A new PET/CT scanner prototype has shown promising results in preclinical testing, offering higher resolution and accurate tumor assessment. The scanner aims to enhance treatment planning for head and neck cancers, which have a low five-year survival rate and high recurrence rate.
A large population study reveals that common cancer symptoms are pervasive across all types of cancer and sociodemographics, with higher symptom burdens among patients with lung, gastrointestinal, and gynecologic cancers. The study highlights the importance of prioritizing symptom management in patients who need or desire treatment.
Research outlines actionable steps to address longstanding health disparities in breast cancer screening and treatment options. Surgeons can drive change by maintaining awareness of existing disparities and providing additional resources to patients.
Researchers found that COVID-19 vaccination generates robust T cell responses in haematology patients, on par with healthy individuals. The study provides key insights for future immunisation strategies and shows that mRNA vaccines can elicit strong T cell immunity in patients with co-morbidities.
A new drug combination has doubled the expected time until cancer progression in heavily resistant head and neck cancer patients. The treatment, which includes a monoclonal antibody drug called ficlatuzumab, has shown an unusually high response rate of 38% in HPV-negative patients.
Scientists have engineered a unique strain of probiotic bacteria to over-express a metal transporter that binds and concentrates copper, facilitating the delivery of radionuclide therapy to cancer cells. This approach targets tumors without relying on specific receptors, making it potentially effective against treatment-resistant cancers.
A proactive patient education/recruitment program, administered with a nurse navigator, identified 37.3% more eligible patients for low-dose computed tomography (LDCT) screenings for lung cancer. The program led to a 42% increase in LDCT prescriptions among willing and eligible patients.
The NRG-GY018 trial found that pembrolizumab significantly improved progression-free survival outcomes in women with stage III-IV or recurrent endometrial cancer, particularly those with mismatch repair deficient tumors. The treatment also demonstrated improved overall survival and quality of life outcomes.
The ENGOT-EN6-NSGO/GOG-3031/RUBY trial reveals significant improvements in progression-free survival and overall survival for patients with primary advanced or recurrent endometrial cancer when treated with dostarlimab in combination with standard of care carboplatin/paclitaxel. The new treatment regimen offers a substantial increase i...
ENZAMET, a new drug combination, has shown significant improvement in survival rates for men with advanced prostate cancer. After five years, the treatment led to a 67% survival rate, compared to 57% for standard therapy.
A phase II trial investigating the combination of ribociclib and letrozole showed a response rate of 23%, progression-free survival of 19.1 months, and duration of response of 19.1 months in patients with recurrent low-grade serous ovarian cancer.
Women with locally advanced squamous cell carcinoma of the vulva who received gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy exhibited increased rates of pathologic complete responses. The study found improved survival and response outcomes for this population, while minimizing toxicity.
The NRG-GY017 trial found that atezolizumab improved 2-year disease-free survival rates (79% vs. 59%) and pathologically complete or partial responses (69% vs. 40%) for patients with locally advanced cervical cancer. The study also showed a favorable immune response, including positive PD-L1 scoring and T-cell receptor clonal expansion.
Researchers developed an AI-based diagnostic screening system called DeepGlioma to analyze tumor specimens and detect genetic mutations rapidly. The system identified molecular subgroups with high accuracy and has the potential to improve access and speed of diagnosis for patients with deadly brain tumors.
Scientists have identified a new molecule that could help distinguish and treat patients with a specific subgroup of medulloblastoma, the most common malignant brain tumor in children. The discovery points to potential targeted therapies using a drug or drugs to block the molecule's activity.
Researchers identified high expression of glypican-1 in primary solid tumors, correlating with poor prognosis in various cancer types. Suppression of GPC1 attenuated cancer cell proliferation, suggesting its potential as a novel diagnostic tool and target for therapy.
Researchers found that physical activity can prevent cancer recurrence in stage III colon cancer patients by lowering the recurrence rate within the first year of treatment. This association persisted for approximately three years after surgery, suggesting a long-term survival benefit.
A new surgical therapy has proven effective in treating melanoma in the eye that has spread to the liver, with 40% of patients experiencing tumor shrinkage, and offers a promising alternative to current treatments.
A recent review article highlights the significant impact of cancer on Hispanic patients and their caregivers, citing communication barriers, financial difficulties, and sociocultural issues. The study estimates 126,000 new cancer cases diagnosed yearly in Hispanics, placing a substantial burden on family members and friends.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Researchers have found a new solution to combat resistant staphylococcus aureus infections, which can be difficult to treat. Endolysins, a newly developed enzyme, has been shown to kill both resistant and non-resistant staphylococcus aureus without the need for antibiotics.
A new method to cure HIV using umbilical cord blood stem cells has yielded long-term successful results for a middle-aged mixed-race woman with leukemia and HIV. The approach broadens the opportunities for people of diverse ancestry to attain cures.